Skip to main content

Capsaicin 8% Dermal Patch: A Review in Peripheral Neuropathic Pain

Drugs volume 78, pages 1489–1500 (2018)Cite this article

Abstract

The adhesive capsaicin dermal patch (Qutenza®) delivers a high concentration (8% w/w) of synthetic capsaicin, a highly selective agonist of transient receptor potential vanilloid-1 (TRPV-1), directly to the site of pain. The capsaicin 8% dermal patch is indicated in the EU for the treatment of peripheral neuropathic pain (PNP) in adults, either alone or in combination with other medicinal products for pain. In patients with painful diabetic peripheral neuropathy, a single 30-min application of the capsaicin 8% dermal patch provided 12 weeks of pain relief and improved sleep quality compared with placebo. Repeat treatment with the capsaicin 8% dermal patch plus standard of care over 52 weeks provided sustained pain relief, with no negative neurological effects compared with standard of care alone. The capsaicin 8% dermal patch was non-inferior to oral pregabalin in relieving pain in patients with non-diabetic PNP, with a faster onset of action and greater treatment satisfaction. A single 60-min application of the capsaicin 8% dermal patch provided rapid and sustained pain relief in patients with postherpetic neuralgia. Results in patients with HIV-associated neuropathy were equivocal, with a significant improvement in pain intensity observed in one trial, but not in the other. The capsaicin 8% dermal patch was generally well tolerated; transient application-site reactions were the most common adverse events. In conclusion, the capsaicin 8% dermal patch is a useful addition to the treatment options currently available for patients with PNP.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.

    CAS  PubMed  Article  Google Scholar 

  2. Zilliox LA. Neuropathic pain. Continuum. 2017;23(2):512–32.

    PubMed  Google Scholar 

  3. Baranidharan G, Das S, Bhaskar A. A review of the high-concentration capsaicin patch and experience in its use in the management of neuropathic pain. Ther Adv Neurol Disord. 2013;6(5):287–97.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  4. Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 agonist) therapy for pain relief: farewell or revival? Clin J Pain. 2008;24(2):142–54.

    PubMed  Article  Google Scholar 

  5. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490–502.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. European Medicines Agency. Summary of product characteristics: Qutenza 179 mg cutaneous patch. 2017. http://www.ema.europa.eu. Accessed 10 Sep 2018.

  7. Wohlrab J, Neubert RH, Heskamp ML, et al. Cutaneous drug delivery of capsaicin after in vitro administration of the 8% capsaicin dermal patch system. Skin Pharmacol Physiol. 2014;28(2):65–74.

    PubMed  Article  CAS  Google Scholar 

  8. Malmberg AB, Mizisin AP, Calcutt NA, et al. Reduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch. Pain. 2004;111(3):360–7.

    CAS  PubMed  Article  Google Scholar 

  9. Kennedy WR, Vanhove GF, Lu S-P, et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain. 2010;11(6):579–87.

    CAS  PubMed  Article  Google Scholar 

  10. Babbar S, Marier J-F, Mouksassi M-S, et al. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit. 2009;31(4):502–10.

    CAS  PubMed  Article  Google Scholar 

  11. European Medicines Agency. CHMP assessment report for Qutenza. 2009. http://www.ema.europa.eu. Accessed 10 Sep 2018.

  12. Chanda S, Bashir M, Babbar S, et al. In vitro hepatic and skin metabolism of capsaicin. Drug Metab Dispos. 2008;36(4):670–5.

    CAS  PubMed  Article  Google Scholar 

  13. Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2017;18(1):42–53.

    CAS  PubMed  Article  Google Scholar 

  14. Vinik AI, Perrot S, Vinik EJ, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 2016;16(251):1–14.

    Google Scholar 

  15. Perrot S, Ortega E, Vinik EJ, et al. Efficacy, quality of life and treatment satisfaction with capsaicin 8% patch versus standard of care in painful diabetic peripheral neuropathy [abstract no. 1067]. Diabetologia. 2015;58(Suppl. 1):S514.

    Google Scholar 

  16. Haanpaa M, Cruccu G, Nurmikko TJ, et al. Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. Eur J Pain. 2016;20(2):316–28.

    CAS  PubMed  Article  Google Scholar 

  17. Cruccu G, Nurmikko TJ, Ernault E, et al. Superiority of capsaicin 8% patch versus oral pregabalin on dynamic mechanical allodynia in patients with peripheral neuropathic pain. Eur J Pain. 2018;22(4):700–6.

    CAS  PubMed  Article  Google Scholar 

  18. Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7(12):1106–12.

    CAS  PubMed  Article  Google Scholar 

  19. Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011;12:99–109.

    PubMed  Article  Google Scholar 

  20. Backonja MM, Malan TP, Vanhove GF. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med. 2010;11:600–8.

    PubMed  Article  Google Scholar 

  21. Simpson DM, Gazda S, Brown S, et al. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage. 2010;39(6):1053–64.

    CAS  PubMed  Article  Google Scholar 

  22. Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70(24):2305–13.

    CAS  PubMed  Article  Google Scholar 

  23. Clifford DB, Simpson DM, Brown S, et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr. 2012;59(2):126–33.

    CAS  PubMed  Article  Google Scholar 

  24. Brown S, Simpson DM, Moyle G, et al. NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials. AIDS Res Ther. 2013;10(1):5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. Simpson DM, Brown S, Tobias JK, et al. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study. Clin J Pain. 2014;30(2):134–42.

    PubMed  Google Scholar 

  26. Maihofner C, Heskamp ML. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin. 2013;29(6):673–83.

    CAS  PubMed  Article  Google Scholar 

  27. Maihofner CG, Heskamp ML. Treatment of peripheral neuropathic pain by topical capsaicin: impact of pre-existing pain in the QUEPP-study. Eur J Pain. 2014;18(5):671–9.

    CAS  PubMed  Article  Google Scholar 

  28. Hansson P, Jensen TS, Kvarstein G, et al. Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice. Eur J Pain. 2018;22(5):941–50.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  29. Mankowski C, Poole CD, Ernault E, et al. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study. BMC Neurol. 2017;17(80):1–11.

    Google Scholar 

  30. Tenreiro Pinto J, Pereira FC, Loureiro MC, et al. Efficacy analysis of capsaicin 8% patch in neuropathic peripheral pain treatment. Pharmacology. 2018;101(5–6):290–7.

    CAS  PubMed  Article  Google Scholar 

  31. Filipczak-Bryniarska I, Krzyzewski RM, Kucharz J, et al. High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience. Med Oncol. 2017;34(162):1–5.

    CAS  Google Scholar 

  32. Levesque A, Riant T, Labat J-J, et al. Use of high-concentration capsaicin patch for the treatment of pelvic pain: observational study of 60 inpatients. Pain Physician. 2017;20(1):E161–7.

    PubMed  Article  Google Scholar 

  33. Aitken E, McColl G, Kingsmore D. The role of Qutenza® (topical capsaicin 8%) in treating neuropathic pain from critical ischemia in patients with end-stage renal disease: an observational cohort study. Pain Med. 2017;18(2):330–40.

    PubMed  Google Scholar 

  34. Zis P, Bernali N, Argira E, et al. Effectiveness and impact of capsaicin 8% patch on quality of life in patients with lumbosacral pain: an open-label study. Pain Physician. 2016;19(7):E1049–53.

    PubMed  Google Scholar 

  35. Marec CLE, Berard J, Queneuille I, et al. Improvement of chemotherapy induced neuropathy (CIN) in cancer patients using capsaicin 8% patch [abstract no. e14031]. J Clin Oncol. 2016;34(15 Suppl).

  36. Reeves K, Tilak D, Putt O. Is an 8% capsicum patch (Qutenza) an alternative to traditional neuropathic pain management following breast surgery [abstract no. 138460]? Reg Anesth Pain Med. 2016;41(5 Suppl.):e116.

    Google Scholar 

  37. Rorbaek M, Ventzel L, Gottrup H. Treatment with topical capsaicin: experience from a pain clinic [abstract no. F34]. Scand J Pain. 2017;3(3):197.

    Article  Google Scholar 

  38. Churruca I. Capsaicin 8% patch in urological patients with neuropathic pain [abstract no. WIP16-0048]. Pain Pract. 2016;16(Suppl. 1):48.

    Google Scholar 

  39. Churruca I, Miro P, Pardina A, et al. Capsaicin (8%) patch in urological patients with neuropathic pain due to scar [abstract]. In: 9th World Congress of the World Institute of Pain. 2018.

  40. Gustorff B, Poole C, Kloimstein H, et al. Treatment of neuropathic pain with the capsaicin 8% patch: quantitative sensory testing (QST) in a prospective observational study identifies potential predictors of response to capsaicin 8% patch treatment. Scand J Pain. 2017;4(3):138–45.

    Article  Google Scholar 

  41. Bardo-Brouard P, Luizard C, Valeyrie-Allanore L, et al. High-concentration topical capsaicin in the management of refractory neuropathic pain in patients with neurofibromatosis type 1: a case series. Curr Med Res Opin. 2018;34(5):887–91.

    CAS  PubMed  Article  Google Scholar 

  42. Privitera R, Birch R, Sinisi M, et al. Capsaicin 8% patch treatment for amputation stump and phantom limb pain: a clinical and functional MRI study. J Pain Res. 2017;10:1623–34.

    PubMed  PubMed Central  CAS  Article  Google Scholar 

  43. Peppin JF, Majors K, Webster LR, et al. Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain. J Pain Res. 2011;4:385–92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. Abdulahad AK, Snijder RJ, Panni MK, et al. A novel standard to evaluate the impact of therapeutic agents on patient safety—the BURDEN OF THERAPY©. Contemp Clin Trials Commun. 2016;4:186–91.

    PubMed  PubMed Central  Article  Google Scholar 

  45. Galvez R, Navez ML, Moyle G, et al. Capsaicin 8% patch repeat treatment in nondiabetic peripheral neuropathic pain: a 52-week, open-label, single-arm, safety study. Clin J Pain. 2017;33(10):921–31.

    PubMed  Article  Google Scholar 

  46. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.

    PubMed  Article  Google Scholar 

  47. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review, meta-analysis and updated NeuPSIG recommendations. Lancet Neurol. 2015;14(2):162–73.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. National Institute for Health and Care Exellence (NICE). Neuropathic pain—pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings (updated February 2017). 2013. http://www.nice.org.uk/guidance/cg173. Accessed 10 Sep 2018.

  49. Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther. 2017;6(Suppl 1):35–42.

    PubMed  PubMed Central  Article  Google Scholar 

  50. Garnock-Jones KP, Keating GM. Lidocaine 5% medicated plaster: a review of its use in postherpetic neuralgia. Drugs. 2009;69(15):2149–65.

    CAS  PubMed  Article  Google Scholar 

  51. van Nooten F, Treur M, Pantiri K, et al. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther. 2017;39(4):787–803.

    PubMed  Article  CAS  Google Scholar 

  52. Mankowski C, Patel S, Trueman D, et al. Cost-effectiveness of capsaicin 8% patch compared with pregabalin for the treatment of patients with peripheral neuropathic pain in Scotland. PLoS One. 2016;11(3):e0150973.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  53. Armstrong EP, Malone DC, McCarberg B, et al. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. Curr Med Res Opin. 2011;27(5):939–50.

    PubMed  Article  Google Scholar 

Download references

Acknowledgements

During the peer review process, the manufacturer of capsaicin 8% dermal patch was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Hannah A. Blair

Authors
  1. Hannah A. Blair
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hannah A. Blair.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of Interest

Hannah Blair is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

The manuscript was reviewed by: G. Cruccu, Neurological Sciences, Universita La Sapienza, Rome, Italy; G. Hans, Antwerp University Hospital (UZA), Multidisciplinary Pain Center, Edegem, Belgium; L. Reisner, Department of Clinical Pharmacy, University of California at San Francisco, San Francisco, CA, USA.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Blair, H.A. Capsaicin 8% Dermal Patch: A Review in Peripheral Neuropathic Pain. Drugs 78, 1489–1500 (2018). https://doi.org/10.1007/s40265-018-0982-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-018-0982-7